spec sheet12 rows
Alpha-estradiol is 17alpha-estradiol, the C17 epimer of the ordinary human estrogen 17beta-estradiol. Flipping that one hydroxyl group leaves a molecule that still binds estrogen receptor alpha but only weakly, which is why it turns up in two settings that look unrelated: as one of the most reproducible lifespan-extending drugs in the National Institute on Aging Interventions Testing Program, and as a topical scalp solution licensed in Germany for female pattern hair loss under the name alfatradiol. The two settings share a fact that runs through everything below. Its effects are sex-specific to an unusual degree. The lifespan extension happens in male mice and not female ones [1], it disappears when males are castrated [3], and every controlled human trial of the topical form was run in women. A compound that improves one sex and does nothing measurable in the other is not a compound where a general recommendation is possible.
- Mild feminizing effects; the compound is a weak estrogen, not a non-estrogenic one.
- More menstrual irregularities than minoxidil alone in the one randomized trial reporting a safety difference, using a related synthetic estrogen.
- Depletion of primordial ovarian follicles in growth hormone receptor knockout mice, an ovarian aging signal absent in wild-type littermates.
- Inhibition of hair growth in male mice given it topically, the reverse of the intended effect.
Mechanism
Alpha-estradiol binds receptor alpha, and most of its measured effects are thought to run through it [11]. It is far weaker at that receptor than 17beta-estradiol, which is where the older description of it as a non-feminizing came from; the current review of the field calls it mildly feminizing instead, and states plainly that the feminizing effects are reduced rather than absent [11]. In male mice the downstream picture is metabolic.
Treatment improves sensitivity and glucose tolerance, raises hepatic mTORC2 signalling and activity, and phosphorylates FOXO1a, and none of those changes appear in females given the same drug [3]. Untargeted metabolomics of liver, muscle and plasma found a distinctly male response, with higher amino acid abundance and altered urea cycling, plus male-specific accumulation of a second estrogenic steroid, suggesting the drug is metabolised differently in the two sexes [2].
It also lowers inflammation in specific tissues, including the [7], adipose tissue [8] and the aging brain [6], and it shares MAPK-pathway effects with rapamycin and acarbose, the two other interventions that extend mouse lifespan most reliably [9]. In skin the mechanism is different again and better described than most people assume.
Applied to intact human anagen hair follicles, alpha-estradiol raises aromatase activity in a concentration- and time-dependent way, pushing testosterone toward 17beta-estradiol and androstenedione toward estrone; follicles from female donors express considerably more aromatase to begin with than follicles from male donors [22]. It is not a DHT blocker. Cultured human keratinocytes, fibroblasts and dermal papilla cells given testosterone alongside alpha-estradiol showed that its effect in androgenetic alopecia is not due to 5-alpha-reductase inhibition [23], and in rats it failed to lower prostate 5-alpha-reductase-2 expression under conditions where genistein did [16].
receptor fingerprint
receptor alpha (ERalpha)weak agonist; most measured effects are attributed to this receptor
Aromatase (CYP19A1) in the hair follicleinduces activity; concentration and time dependent in intact human anagen follicles ex vivo
5-alpha-reductasenot inhibited; this is a negative result, stated because the opposite is widely assumed
Hepatic mTORC2 and signallingraises mTORC2 activity, Akt phosphorylation and FOXO1a phosphorylation, in males only
Tissue inflammation (hypothalamic, adipose, neural)lowers inflammatory signalling in a sex-specific pattern
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
The systemic profile in humans is essentially unstudied, because no human has been given this compound systemically in a published trial. What is known comes from two places. First, the feminization question: the framing of alpha-estradiol as non-feminizing is not supported, and the 2026 review of the field is titled to say so, describing mild feminizing effects alongside the metabolic ones [11]. It is an estrogen with the potency turned down, not an estrogen with the estrogenic activity removed. Second, the topical trials, which are the only controlled human exposure. Scalp solutions at 0.025 percent and 0.05 percent were well tolerated over six to twelve months in women, with tolerability reported as comparable to minoxidil [18] [17].
The one randomized trial that reported a safety difference used a related synthetic estrogen rather than this molecule, and found more menstrual irregularities in the estrogen arm than in the minoxidil-only arm [21], which is the kind of signal a systemically absorbed estrogen would be expected to produce. Two animal findings deserve to be stated rather than buried.
In growth hormone receptor knockout mice, alpha-estradiol depleted primordial ovarian follicles, an ovarian aging effect that did not appear in wild-type littermates [12]. And in male mice, topical alpha-estradiol was a potent inhibitor of hair growth, the opposite of its effect in females, in a study designed specifically to compare the sexes [25]. Long-term systemic use in humans has no safety data at all. Research use.
History
Alpha-estradiol arrived from two directions at once. In dermatology it has been available in Europe for decades as a topical solution for androgenetic alopecia, sold in Germany as Ell-Cranell alpha at 0.025 percent, one of a small group of estrogen scalp preparations licensed there for women [17]. Reviews of hair therapeutics from the early 2000s already listed it as the alternative for women unwilling to take systemic hormones, while noting that its efficacy had not been proven to the standard minoxidil had met [24]. In gerontology it arrived through the National Institute on Aging Interventions Testing Program, which tests candidate longevity drugs in genetically heterogeneous mice in parallel at three independent sites and publishes every result.
Alpha-estradiol was included as a weakly estrogenic agonist, extended male lifespan, and then did it again at a threefold higher dose, this time lengthening maximal as well as median lifespan and still only in males [1]. Later work showed the benefit survives a late start, appearing in mice first treated at sixteen months and in a separate cohort treated even later in life [4] [5]. It has since become one of the standard reference compounds for asking why anti-aging interventions so often work in one sex and not the other [15].
Reputation
It is sold in the research chemical market as a longevity compound and, increasingly, as a nootropic. The longevity half of that has a real basis and a real limit. The nootropic half does not: no study in the record measures cognition in humans, and the neurological work that exists measures inflammatory markers in aging mouse brains rather than performance at anything [6]. The second recurring claim is that it is non-feminizing, which is a stronger word than the evidence carries and which the most recent review contradicts in its own title [11]. Among people using it for hair, its reputation is roughly accurate: it is regarded as a mild option that slows loss rather than reversing it, which is what the controlled comparison found [18].
Subjective profileweighing the evidence above
Real, well-replicated evidence, attached to a claim that is narrower than the one being sold. The mouse lifespan work is among the strongest in the field and it is male-only and gonad-dependent, so it is not a general longevity agent. The human evidence is entirely topical, entirely in women, and in the two comparisons that had a control arm it came second to minoxidil and second to topical finasteride. Nothing published supports the cognitive claim it is often marketed under. Worth understanding; not worth buying on the strength of the label.
Resources
This entry is here for reference.
Research
- 1999first citedEffects of 17-beta-estradiol and ICI 182 780 on hair growth in various strains of mice.
- 2007controlled trialComparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treat…
- 2017most active year3 papers
- 2026most recent17α-Estradiol: A mildly feminizing estrogen with sex-specific metabolic and lifespan benefits.
- 1.Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer.
- 2.Male lifespan extension with 17-α estradiol is linked to a sex-specific metabolomic response modulated by gonadal hormones in mice.
- 3.Sex differences in lifespan extension with acarbose and 17-α estradiol: gonadal hormones underlie male-specific improvements in glucose tolerance and mTORC2 signaling.
- 4.17-α estradiol ameliorates age-associated sarcopenia and improves late-life physical function in male mice but not in females or castrated males.
- 5.17-a-estradiol late in life extends lifespan in aging UM-HET3 male mice; nicotinamide riboside and three other drugs do not affect lifespan in either sex.
- 6.17-α-Estradiol Has Sex-Specific Effects on Neuroinflammation That Are Partly Reversed by Gonadectomy.
- 7.Anti-aging drugs reduce hypothalamic inflammation in a sex-specific manner.
- 8.Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging.
- 9.Rapamycin, Acarbose and 17α-estradiol share common mechanisms regulating the MAPK pathways involved in intracellular signaling and inflammation.
- 10.Healthy Aging Interventions Reduce Repetitive Element Transcripts.
- 11.17α-Estradiol: A mildly feminizing estrogen with sex-specific metabolic and lifespan benefits.
- 12.17α-Estradiol promotes ovarian aging in growth hormone receptor knockout mice, but not wild-type littermates.
26 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is it true that this is a non-feminizing estrogen?
No, and the claim should be retired. It is a weak estrogen, not an inactive one. The 2026 review of the compound is titled "17alpha-Estradiol: A mildly feminizing estrogen with sex-specific metabolic and lifespan benefits", and describes the feminizing effects as mild rather than absent [11]. The useful version of the claim is that it produces less feminization per unit of metabolic effect than 17beta-estradiol does, which is a real and interesting property; the marketing version, that it can be taken without estrogenic effects, is not supported.
Does the mouse lifespan data mean anything for a woman?
Very little, and that is the most important thing to know about this compound. In the Interventions Testing Program it extended lifespan in male mice and not in female mice, at every dose tested [1]. The metabolic improvements that come with it are also male-only [3], as are the muscle and physical function benefits [4]. This is not a case of a smaller effect in females; it is a null result in females. Any extrapolation to women would have to be built on something other than the lifespan literature, and there is nothing there to build on.
Why would castration remove the benefit if it is an estrogen?
Because the effect depends on male gonadal hormones being present rather than working around them, which is counterintuitive and well documented. Castrated males show far fewer of the metabolic responses that intact males show, and only those responses that intact females also show [3]. Almost the entire male-specific metabolomic signature is inhibited or reduced by castration [2]. The muscle and physical function effects behave the same way, appearing in intact males but not in castrated ones [4]. Whatever the mechanism is, it requires an intact male endocrine background to operate in.
Is this a nootropic?
There is no evidence that it is. Nothing in the published record measures human cognition on this compound, at any dose, by any route. The nearest work is a study of neuroinflammation in aging mice, which found sex-specific effects on inflammatory markers that were partly reversed by gonadectomy; that is a measurement of brain tissue, not of thinking [6]. A compound can be sold in a nootropic catalogue without having a nootropic literature, and this is one of them.
Should I use it for hair loss instead of minoxidil?
The controlled comparison says no. In women randomized to 2 percent minoxidil twice daily or 0.025 percent alfatradiol once daily, minoxidil significantly increased cumulative hair thickness and hair density over six months while those same measures stayed nearly unchanged on alfatradiol; the authors described alfatradiol as decelerating or stabilising loss rather than producing regrowth, and both were well tolerated [18].
Against topical finasteride the result went the same way, with finasteride significantly ahead at six months and again at twelve to eighteen [19]. Open-label studies without a comparator do report gains in hair count and calibre [17] [20], which is exactly the gap you would expect between an uncontrolled and a controlled design. And one randomized trial adding a related synthetic estrogen to minoxidil found no significant advantage over minoxidil alone, with more menstrual irregularities [21].
Does it work on the scalp the same way in men?
The available evidence points the other way, which is worth pausing on before buying it. The human trials were run in women. The mechanism proposed for those trials is induction of follicular aromatase, and human hair follicles from female donors carry considerably more aromatase than follicles from male donors [22]. In the one study that compared the sexes directly, topical alpha-estradiol was a potent inhibitor of hair growth in male mice while behaving differently in females [25]. That is animal data and should not be over-read, but it is the only sex comparison there is, and it does not favour male use.
Is it just estradiol under a different name?
No. It is the same molecular formula with the hydroxyl group at carbon 17 in the opposite orientation, which makes it a stereoisomer, not a salt or an ester. That single change drops its affinity at estrogen receptor alpha sharply, and the entire pharmacological profile follows from the drop [11]. Estradiol valerate and conjugated estrogens are delivery variations on 17beta-estradiol and behave like it; this one does not.
How strong is the longevity evidence compared to other compounds?
For a male mouse, unusually strong. The Interventions Testing Program runs each compound at three independent sites in genetically heterogeneous mice and publishes everything, which is a much harder test than a single-lab lifespan study, and alpha-estradiol extended both median and maximal lifespan there at the higher dose [1]. It works started late in life as well as early [5], and it shows the tissue-level changes you would want to see alongside a survival curve: less adipose and hypothalamic inflammation [8] [7], fewer repetitive element transcripts [10], preserved muscle and grip strength [4], and coherent lipid shifts across organs [14]. All of it is in male mice, and none of it has been tested in a human.
Limitations of the evidence
- No human has been given this compound systemically in a published trial, so the entire longevity case rests on mice.
- The lifespan effect is male-only and is lost after castration, so it cannot be described as a general anti-aging intervention.
- Every controlled human trial is topical, in women, with a hair endpoint; none measured metabolism, cognition or survival.
- The two positive human hair studies most often quoted are open-label and non-comparative, and the two studies with a comparator both placed it behind the comparator.
- There is no published human pharmacokinetic study for any systemic route, so nothing anchors a dose.
Adverse effects
- Mild feminizing effects; the compound is a weak estrogen, not a non-estrogenic one.
- More menstrual irregularities than minoxidil alone in the one randomized trial reporting a safety difference, using a related synthetic estrogen.
- Depletion of primordial ovarian follicles in growth hormone receptor knockout mice, an ovarian aging signal absent in wild-type littermates.
- Inhibition of hair growth in male mice given it topically, the reverse of the intended effect.
Notes and cautions
- The single most useful fact about this compound is that its direction of effect changes with sex, and in the follicle it may change with sex as well as with tissue.
- It is not a DHT blocker; that mechanism was tested in human skin cells and specifically ruled out.
- Its longevity result is a reference point in the field precisely because it is sexually dimorphic, which is why it appears in reviews about why interventions work in one sex.